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Abstract: Epidemiological studies have been used to show associations between modifiable lifestyle
habits and the incidence of breast cancer. Among such factors, a history of alcohol use has been reported
in multiple studies and meta-analyses over the past decades. However, associative epidemiological
studies that were interpreted as evidence that even moderate alcohol consumption increases
breast cancer incidence have been controversial. In this review, we consider the literature on the
relationship between moderate or heavy alcohol use, both in possible biological mechanisms and
in variations in susceptibility due to genetic or epigenetic factors. We argue that there is a need to
incorporate additional approaches to move beyond the associations that are reported in traditional
epidemiological analyses and incorporate information on molecular pathologic signatures as a
requirement to posit causal inferences. In particular, we point to the efforts of the transdisciplinary
field of molecular pathological epidemiology (MPE) to evaluate possible causal relationships, if any,
of alcohol consumption and breast cancer. A wider application of the principles of MPE to this field
would constitute a giant step that could enhance our understanding of breast cancer and multiple
modifiable risk factors, a step that would be particularly suited to the era of “personalized medicine”.
Keywords: alcohol; breast cancer; epidemiology; risk factors; genetics; epigenetics; molecular
pathological epidemiology; meta-analysis; moderate drinking
1. Introduction
Breast cancer presents as solid tumors that originate in breast tissue due to deleterious mutations in
different cell types, most commonly originating in ductal epithelium. As is true for most cancers, there are
multiple subtypes, which have different etiologies and require different treatments. Breast cancer
remains a global concern notwithstanding the 2015 National Cancer Institute fact sheet [1], stating that
overall breast cancer death rates continued to decrease in the United States in the period between 1990
and 2014 (from 33.1 to 20.5 per 100,000 women). Breast cancer represents the second most common
female malignancy worldwide and is one of the primary causes of death among women globally [2].
All cancers are subject to a combination of intrinsic and accidental factors that reflect the balance
of the impact of inborn as well as incidental deleterious mutations and the intrinsic cellular and tissue
repair and other defense mechanisms available in an individual. A vast literature exists aimed at
differentiating between such intrinsic and modifiable risk factors. Epidemiological studies have been
used extensively to address these questions.
In this review, we focus in particular on epidemiological studies that have attempted to assess the
role of alcohol consumption as a risk factor in the development of breast cancer. Epidemiology applies
statistical approaches to identify associative relations; such studies by themselves are intrinsically
less suitable to identify causal relationships: Establishing causality requires additional information.
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Furthermore, apart from complications due to confounding factors that may be difficult to assess,
the validity of the association depends critically on the quality of the variables of interest, in this case,
the reliability of the information on respondents’ alcohol consumption, both in quantities consumed
and drinking profile, throughout an individual’s history relevant to disease onset and progression.
Alcohol use history is almost invariably estimated based on self-reporting and averaged over shorter
or longer time periods. This is particularly problematic when investigating the association of more
moderate alcohol use with breast cancer incidence. Our goal is to provide a more detailed evaluation
of the arguments in support of the validity of the suggested causality between alcohol drinking,
and in particular moderate drinking, and the incidence and progression of breast cancer. We will
consider possible mechanisms that could underlie such a relationship and emphasize the need for
supplementary evidence, be it biological plausibility or pathological supportive information, that could
help strengthen the scientific basis on which conclusions are based.
1.1. Molecular Characteristics of Breast Cancer Subtypes
Breast cancer is a heterogeneous disease that was classified by the World Health Organization
(WHO) [3] to encompass 21 distinct histological types. Roughly 95% of invasive breast cancers
are adenocarcinomas that originate in the epithelial tissue of the terminal duct lobular unit [4].
DNA microarray and next-generation sequencing technology has been used to characterize gene
expression in breast cancer and identify its molecular subtypes. In addition, immunohistochemical
stains are routinely used to identify the status of hormone receptors: estrogen receptor (ER),
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). The molecular
and clinical heterogeneity shown by specific gene expression signatures can predict mortality risk,
metastasis and survival [5].
Breast cancers have been classified [6] into five major subtypes. (1) luminal A (ER and/or
PR-positive, HER2-negative); (2) luminal B (ER-positive and/or PR-positive, HER2-positive); (3) HER2
overexpressing (ER-negative, PR-negative, HER2-positive); (4) basal-like (ER-negative, PR-negative,
HER2-negative, cytokeratin 5/6-positive, and/or HER2-positive); and (5) unclassified breast tumors [7].
Tumors in subtypes four and five have a triple-negative (TN) phenotype (ER-negative, PR-negative,
HER2-negative); however, approximately 70% of TN tumors are basal-like [8]. Risk factors associated
with ER-positive and PR-positive breast tumors involve mechanisms related to endogenous hormones,
whereas the genesis of ER-negative and PR-negative breast cancers may be non-hormonal [9].
The cell origin of breast cancer has been debated. Two models (not mutually exclusive) have been
advanced: The sporadic clonal evolution model (stochastic), which suggests that any epithelial cell can
undergo random mutations that compete for survival and progression; and the cancer stem cell model
(hierarchical) which postulates that stem cells give rise to the tumor or were acquired within the tumor
and, due to their self-renewal ability, maintain tumorigenesis [10].
1.2. Risk Factors for Breast Cancer
Breast cancer is a multifactorial disease resulting from a series of interactions between genetics,
environmental factors, immune response, and even breast microbiota. A multitude of factors,
both modifiable and non-modifiable, can contribute to the risk of breast cancer. While some mutations
can be inherited at birth, the majority are acquired later in life due to various risk factors.
The strongest non-modifiable primary risk factors for breast cancer include aging; reproductive
parameters which determine the cumulative lifetime estrogen exposure [early menarche (before age 12);
delayed menopause (after age 55); delayed childbearing (first full-term pregnancy after age 30);
miscarriage; abortion]; and genetics (inherited changes in certain genes and family history of breast
cancer) [11].
Various modifiable lifestyle risk factors have been identified, including dietary habits (consumption of
polyunsaturated fats and excessive alcohol), smoking, exposure to radiation or synthetic estrogens,
physical inactivity, use of hormone-replacement therapy (HRT) or diethylstilbestrol, obesity, diabetes,
Cancers 2018, 10, 349 3 of 27
breast implants, epigenetic factors, viruses (e.g., Epstein-Barr virus, or EBV; human papillomavirus,
or HPV), occupational exposure to chemicals (e.g., polychlorinated biphenyls, or PCBs; solvents;
and exposure to endocrine-active chemicals that can disrupt typical endocrine behaviors), exposure to
pesticides and air pollution, and even night-shift work. Needless to say, other risk factors may exist
that have not yet been fully identified. For example, a higher relative abundance of bacteria that have
the ability to cause DNA damage, and a decrease in some anticarcinogenic lactic acid bacteria were
detected in breast cancer patients, which raises the question of the role of the mammary microbiome in
modulating the risk of breast cancer development [12].
The risk attributable to modifiable and non-modifiable factors was calculated in a German
population-based, case-control study of postmenopausal breast cancer [13]. The attributable risk
for non-modifiable risk factors was 37.2% regarding overall invasive tumors; 36.5% for ER+/PR+
tumors; 47.9% for ER+/PR− tumors; and 31.1% for ER−/PR− tumors. Of the modifiable risk
factors, hormone replacement therapy and physical inactivity had the highest impact on breast
cancer-attributable risk (19.4% and 12.8% respectively for overall invasive tumors; 25.3% and 16.6%,
respectively, for ER+/PR+ tumors). Odds ratios for alcohol consumption and body mass index (BMI)
were not statistically significant regarding invasive breast cancer risk. Different risk factors were
associated with specific types of breast cancer; for example, obesity was associated with increased
risk of the TN subtype, while older age and use of hormone replacement therapy was associated with
increased risk of HER2 overexpressing tumors [6].
In the following sections we will briefly discuss genetic and epigenetic risk factors to highlight
the complexity of breast cancer etiology and to point to the impact of alcohol use as a modifiable risk
factor in specific genetic and epigenetic contexts. A better understanding of such gene-environment
interactions may help identify potential biological pathways and shed light on breast cancer etiology.
1.2.1. Genetic Factors
The incidence of breast cancer in first-degree relatives of women with the disease is about twice
that of the general population [14]. Thus, the disease exhibits familial aggregation. However, the majority
of breast cancers are not hereditary and occur in the absence of a first-degree family history of breast cancer.
Breast cancer susceptibility genes can be categorized as high-, moderate-, or low-penetrance based
on the relative risk of breast cancer associated with these genes’ mutations. These susceptibility genes
were discussed by Apostolou and Fostira in 2013 [15], and 84 independent loci have been identified by
Genome-wide association studies (GWAS) [16].
High-penetrance genes, such as BRCA1, BRCA2, p53, PTEN, STK11, and CDH1 are associated
with a relative risk of breast cancer development higher than 5.
Mutations in two prominent susceptibility genes, BRCA1 and BRCA2, were identified as major
risk factors for breast cancer [17,18]. However, the incomplete penetrance of these mutations suggests
that other factors—environmental, hormonal, or modifier genes—may modify that risk. This is
illustrated by a study in which monozygotic (MZ) twins who carried identical BRCA1 gene mutations,
resulted in discordant phenotypes: One had breast cancer twice in 27 years while her MZ twin
remained healthy [19]. BRCA1-associated cancers are more likely to present specific characteristics
like the absence of ER, PR, and HER2 receptors [20,21], unlike BRCA2-related cancers, which usually
express ER and PR. Examination of the role of BRCA1 and BRCA2 in the DNA damage response has
led to the identification of several breast cancer susceptibility genes such as FALB2, CHEK2, BRIP1,
all of which interact directly or indirectly with BRCA1 or BRCA2 [22]. Other studies reported that
alcohol consumption does not appear to increase breast cancer risk in premenopausal young women
carrying a BRCA gene mutation [23,24].
Moderate-penetrance genes confer a relative increase in the risk of breast cancer between 1.5
and 5 [25]. GWAS have identified genetic susceptibility variants of medium-penetrance which confer
an increased risk per allele of 2 to 3. These include variants in PALB2 (which encodes a protein
colocalizing with BRCA2) [26]; checkpoint kinase 2 (CHEK2) [27]; ataxia telangiectasia mutated
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(ATM) [28]; and BRCA1-interacting protein C-terminal helicase 1 (BRIP1) [29]. Studies on TN breast
cancer patients showed associations of breast cancer with mutations in moderate penetrance breast
cancer susceptibility genes FALB2, BARD1, BRIP1, RAD51C, and RAD51D [30].
Low-penetrance genes are associated with a relative increase in the risk of breast cancer of
about 1.5. Four loci were identified that exhibited consistent association with breast cancer and
contain plausible causative genes [31]: fibroblast growth factor receptor 2 (FGFR2); TOX high mobility
group box family member 3 (TNRC9); mitogen-activated protein kinase kinase kinase 1 (MAP3K1);
and lymphocyte-specific protein 1 (LSP1).
The susceptibility to breast cancer is polygenic; i.e., conferred by a large number of loci, each with
limited contribution to breast cancer risk [32]. Some of the low-penetrance alleles are more specific to
ER-negative or TN tumors, particularly in younger women (less than 50 years of age). These include
telomerase reverse transcriptase (TERT) [33] and ethylene response sensor 1 (ERS1) [34]; while others
(e.g., FGFR2) are more specific for ER-positive breast cancer [35].
Additional susceptibility loci have been identified for breast cancer in several recent studies.
For example, a 2014 study showed association between breast cancer risk and seven breast cancer
susceptibility loci (FGFR2, TOX3, STXBP4, SLC4A7, LSP1, 2q35, and 5p12) [36]. A genome-wide
association study identified 25 known breast cancer susceptibility loci as risk factors for TN breast
cancer. Another study confirmed an association with TN breast cancer for 10 loci (LGR6, MDM4,
CASP8, 2q35, 2p24.1, TERT-rs10069690, ESR1, TOX3, 19p13.1, RALY), and identified 15 additional
breast cancer loci (PEX14, 2q24.1, 2q31.1, ADAM29, EBF1, TCF7L2, 11q13.1, 11q24.3, 12p13.1, PTHLH,
NTN4, 12q24, BRCA2, RAD51L1-rs2588809, and MKL1) [37]. In addition, a 2013 meta-analysis of
nine genome-wide association studies (including 10,052 breast cancer cases of European ancestry)
identified 41 new loci associated with breast cancer risk [38]. A 2014 genome-wide association analysis
of more than 120,000 individuals identified 15 new susceptibility loci for breast cancer [39]. By using
methods accounting for gene-environment interaction, researchers identified three single-nucleotide
polymorphisms, or SNPs (rs12197388 on chromosome 6; rs10483028 and rs2242714 on chromosome
21), showing a statistically significant association between 10 environmental variables and risk for
breast cancer [40].
Other risk factors reported for breast cancer include mutations in the p53-inducible
protein phosphatase PPM1D (protein phosphatase, Mg2+/Mn2+ dependent, 1D) [41], MTHFR
(methylenetetrahydrofolate reductase), Ala222Val gene polymorphisms [42], and APOBEC3B
(apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3B) overexpression [43].
Studies [44,45] conducted about a decade ago showed that the D302H polymorphism in CASP8
(caspase 8, rs1045485) could reduce breast cancer risk. Further studies confirmed this protective effect
and showed that the per-allele odds ratio is 0.88 for the CASP8 D302H (rs1045485) [46].
The above discussion demonstrates the critical role of mutations in tumor suppressors and
oncogenes in the nuclear genome (e.g., BRCA1, BRCA2, p53, PTEN, ATM, CHEK2, HER2) in
breast carcinogenesis.
Compared to nuclear DNA (nDNA), mitochondrial DNA (mtDNA) is more susceptible to
mutations due to limited repair mechanisms. In breast cancer, mitochondrial function is severely
impaired [47]. One early event in breast carcinogenesis can be mutations in mtDNA that destabilize
the oxidative phosphorylation system (OXPHOS). In addition, various pro- and anti-apoptotic
family proteins regulate glycolysis and respiration [48], and OXPHOS defects could lead to
suppression of apoptosis or enhancement of mitophagy in breast cancer cells. Numerous alterations
in mtDNA in breast cancer have been reported, including point mutations, mtDNA depletion,
microsatellite instability, and insertions [49–53]. SNPs in mtDNA, including G9055A, T239C, C16207T,
T16519C, and A263G [54], were found to increase breast cancer risk, while others (T3197C, G13708A)
were found to decrease breast cancer risk [55].
The incidence of invasive breast cancer or its precursor lesion, ductal carcinoma in situ (DCIS),
increases at an exponential rate until menopause, followed by a slower rate of increase, supporting the
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notion that breast cancer biology is age dependent. Early-onset breast cancer, therefore, could largely
represent inherited mutations (BRCA1, BRCA2, p53, ATM, or PTEN) or early, life-transforming events
that affect the immature mammary cells, whereas later-onset breast cancer may be associated with
environmental or lifestyle factors [56]. While susceptibility loci discussed above are by no means an
exhaustive list, it shows the polygenic nature of breast cancer and the complexity of various genes
(and environment) interactions in breast carcinogenesis.
To what extent these susceptibility loci influence the impact of alcohol consumption on the actual
breast cancer development has received scant attention. Several factors have to work in concert to affect
alcohol toxicity. For example, a recent study in a mouse model of hematopoietic stem cells reported that
the Fanconi anemia DNA-repair pathway counteracts the genotoxic effects of acetaldehyde produced
by alcohol metabolism. Only animals with combined inactivation of aldehyde catabolism (through
Aldh2 knockout—ALDH2, the mitochondrial aldehyde dehydrogenase that is primarily responsible
for oxidation of acetaldehyde) and the Fanconi anemia DNA-repair pathway (Fancd2 knockout)
display susceptibility to the toxic effects of ethanol; the Fanconi anemia pathway prevents aldehyde
lesions from degenerating into DSBs [57]. A critical role for acetaldehyde and oxidative stress damage
in alcohol-associated liver and esophageal cancer has been described in the studies by Seitz and
coworkers [58] and others. Similarly, alcohol-induced damage to mitochondrial function has been
well established, particularly at higher levels of alcohol use [59,60]. These studies also point to the
requirement for significant acetaldehyde accumulation before any of these effects of alcohol exposure
can be detected. For instance, extensive studies on the health consequences of alcohol use on individuals
carrying a defective copy of ALDH2, primarily from East Asian counties, has highlighted the increased
risk for esophageal cancers [61]. Thus, these studies support the interpretation that alcohol enhancement
of DNA damage and interference with mitochondrial quality control are detectable only at relatively high
levels of alcohol consumption. To what extent lower levels of acetaldehyde can exert damaging effects
over a prolonged period of exposure remains insufficiently established.
1.2.2. Epigenetic Modifications
As described above, mutations in oncogenes and tumor-suppressor genes, and chromosomal
abnormalities result in specific gene expression profiles that are characteristic of distinct types of
breast cancer and their responses to treatment. These genes are involved in the regulation of cellular
homeostasis, including cell proliferation, DNA repair, and survival. However, mammary stem cells
undergoing differentiation to primitive progenitor cells that give rise to luminal and myoepithelial
progenitors, which in turn differentiate into epithelial subtypes, are under epigenetic control.
Epigenetic mechanisms, which result in changes in gene expression patterns without altering DNA
sequence, contribute to the mammary gland’s developmental phases from fetal to menopause,
as well as in breast carcinogenesis, by changing gene expression patterns for cell differentiation,
proliferation and apoptosis. Two major classes of epigenetic modulation include DNA methylation
and covalent modifications of histones that determine DNA accessibility. In addition, a multitude
of additional mechanisms exist that determine the fate of mRNA, e.g., through differential splicing,
or by altering mRNA stability or translation, including through effects of non-coding RNAs such
as microRNA (miRNA) and various long non-coding RNAs (lncRNAs), as well as other mRNA
modification mechanism [62]. Below, we will briefly discuss these epigenetic mechanisms, as potential
mechanisms by which alcohol use may induce changes in the gene expression profiles associated
with tumorigenesis.
DNA methylation involves the transfer of a methyl group from the global methyl donor S-adenosyl
methionine (SAM)—predominantly by a set of core DNA methyltransferases (DNMTs)—onto the
5′-position of the cytosine residue in the CpG islands (Figure 1).
SAM is generated in the methionine cycle by condensing ATP with methionine, which itself is
generated by re-methylation of homocysteine (Figure 2). This process involves the transfer of a methyl
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group to homocysteine either from N5-methylene tetrahydrofolate (THF) by methionine synthase,
or from betaine, by betaine homocysteine methyl transferase (BHMT) [63].
The CpG islands, which exist in about 70% of gene promoters, are generally unmethylated [64];
their methylation results in transcriptional silencing. Importantly, there is considerable literature
suggesting that changes in CpG methylation affect the expression and regulation of cancer-related
genes. CpG methylation in promoter regions of tumor-suppressor genes (e.g., BRCA1, VHL and
p16Ink4a) leads to the inactivation of these cancer-preventing proteins. Hypermethylation of
numerous genes, whose biological functions include hormone regulation (ERα, ERβ and PR); DNA repair
(BRCA1, MGMT, MLH1, and GST3); cell cycle regulation (p16Ink4a, cyclin D2, p14ARF, p57KIP2);
apoptosis (DAPK1, HOXA5, TMS1, TWIST, FHIT, GPC3); cell-growth inhibition (RARβ, TGFβRII, SOCS1,
RASSF1A, HIN1, NES1, SYK, WIF1); angiogenesis (maspin and THBS1); invasion (TIMP3, E-cadherin);
and metastasis (APC, TIMP3), has been identified in breast tumors [65].
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could reactivate proto-oncogenes (such as synuclein γ, ID4, urokinase, N-cadherin, β-catenin, and annexin
A4), which are associated with tumor metastasis and drug resistance to endocrine therapy [73].
There is large literature indicating that alcohol consumption can affect the DNA methylation
state, both in analyses on human patients and in studies on experimental animals. Some of these
changes may be associated with a suppression of the availability of the methyl donor SAM through
effects on the methionine cycle (Figure 2). For instance, chronic alcohol feeding to rats for 9 weeks
resulted in a decrease in hepatic concentrations of SAM and methionine, as well as 40% reduction in
DNA methylation [74]. Christensen and colleagues [75] showed that increasing alcohol intake had a
strong trend toward decreased DNA methylation. However, other studies have shown that alcohol
consumption was associated with differential alterations in methylation patterns for several genes,
e.g., hypermethylation of the ER-α [76] and E-cadherin genes and hypomethylation of p16 [77].
Chronic heavy alcohol use can also affect the availability of the folate derivative THF as a
methyl donor for methionine synthesis. There is considerable evidence that chronic alcohol use
can impair folate uptake and cause folate deficiency, which is likely to affect folate methylation
pathways [78]. Thus, low folate levels could promote carcinogenesis by influencing the extent of DNA
methylation [79,80] and thereby affect gene expression, DNA integrity and stability [81]. Another way
by which low folate levels may mediate carcinogenesis is by hampering the conversion of dUMP
to dTMP (Figure 2). Inadequate dTMP levels result in nucleotide deficiency, culminating in DNA
strand breaks due to inappropriate incorporation of uracil into DNA in place of thymidine [82].
Furthermore, low dietary folate intake might be associated with breast cancer by hypomethylation
of the ER receptor, which may influence silencing genes [74]. Other components that may work in
concert with folate, such as Vitamin B12 and methionine, may affect carcinogenesis due to their critical
roles in the one-carbon metabolism pathway.
In addition, there is evidence that a woman’s genotype for the MTHFR variant modulates the effect
of alcohol consumption on breast cancer risk. For example, women with the TT genotype are at a higher
risk of breast cancer than those with other genotypes. In postmenopausal women, the breast cancer
risk was increased in women with the C677T MTHFR variant who had high lifetime daily alcohol
intake, suggesting that folate metabolism has an impact on cancer development [83]. Despite these
arguments, a 2014 meta-analysis [84] of 15 prospective cohort studies and one nested case-control
study, including 1,854,013 participants and 24,620 breast cancer patients, showed that dietary folate
intake was not significantly associated with the risk of breast cancer. Alcohol stratification analysis
was conducted based on six prospective studies, and the results indicated no significant association
between high or low dietary folate intake and breast cancer risk. Three of these studies found marked
reductions in breast cancer risk among those who consumed greater amounts of alcohol, while the other
three studies reported that the relationship between folate intake and breast cancer was not modified
by alcohol intake. Furthermore, a 2007 meta-analysis [85] that included only two prospective studies
indicated that high folate intake was associated with a statistically significant decreased risk of breast
cancer among women with moderate or high alcohol consumption. Thus, the role of methyl donor
availability in clinical outcomes mediated by DNA methylation remains a subject for further study.
Histone modification represents another epigenetic mechanism that influences chromatin remodeling
during stem and/or progenitor cell differentiation. The histone “tails” that extend from the nucleosome
contain lysine residues with ε-amino groups that invariably undergo post-translational modifications,
which mainly include methylation, acetylation, phosphorylation, and ubiquitination. Histone tails
can enhance or inhibit the accessibility of transcription factors to target loci. Histone acetylation by
acetyl transferases (HATs); deacetylation by deacetylases (HDACs); methylation by methyltransferases
(HMTs); or demethylation (by histone demethylases; HDMs) further modify chromatin structure.
Acetylation of lysine residues in histones results in an open chromatin structure (euchromatin)
which allows gene transcription. On the other hand, deacetylation of these lysine residues results
in the formation of closed chromatin (heterochromatin) and repression of gene transcription [86].
Methylation of lysine residues results in either activation or repression of chromatin structural
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conformation. Modifications of H4 generally result in the loss of acetylated K16 and tri-methylated K20
forms, culminating in DNA hypomethylation in human tumor cells, including breast cancer [87].
In addition, numerous non-histone proteins have been reported to be substrates for HDACs.
These proteins are involved in transcription (p53, STAT1, STAT3, HMGB, and NFκB), DNA repair
(Wnt signaling, β-catenin), heat shock response (HSP90), and hormone response (ERα) [88].
As is true for DNA methylation, histone modification reactions also depend on the availability
of an adequate supply of methyl donors or acetyl donors. Interference with the operation of the
methionine cycle and the supply of folate and THF could equally limit the rate of histone methylation
at a global level. Similarly, the supply of acetyl CoA for histone acetylation may be altered by the
availability of this metabolic intermediate. Interestingly, although acetyl CoA is normally derived
predominantly from mitochondrial metabolism, which can limit its availability for nuclear acetylation
reactions, alcohol metabolism generates abundant acetate as a metabolic product that is largely released
from the liver to enter the circulation. Other tissues have the capacity to take up acetate and activate
it to acetyl CoA through the cytosolic/nuclear acetyl CoA synthetase-2 (ACSS2). This makes acetyl
CoA available systemically during ethanol metabolism and potentially influences histone (or other
protein) acetylation in multiple tissues [11,89]. To what extent these processes influence tumorigenesis
or tumor progression remains poorly characterized.
Alcohol use, or other environmental factors can also alter the activity and/or expression of
the multiple classes of histone-modifying proteins and their associated factors. As an example,
persistent exposure of mammary gland stem and progenitor cells to different environmental
factors such as xenoestrogens (phthalates, ethinyl estradiol, phytoestrogens) alters their epigenetic
reprogramming during epithelial differentiation [90]. This is mediated, in part, through ERα nuclear
receptors that activate or silence the transcription of target genes [91]. Interactions between ERα
and various enzymes involved in histone modifications (HAT, HDAC, HMT, HDM), co-activators
and co-repressors have introduced another layer of complexity in the epigenetic regulation of breast
carcinogenesis [92]. Moreover, several HDACs (HDAC1, 6 and 8) have been found to be upregulated or
overexpressed in breast cancers and to interact with histone-lysine-specific demethylase 1 (LSD1) and
EZH2, a component of the polycomb repressor complex, playing an important role in the transcriptional
changes involved in breast cancer carcinogenesis.
Epigenetic mechanisms acting through mRNA modifications: There is substantial emerging
evidence for an impact of alcohol intake on epigenetic regulation through modification of mRNA
through splicing factors or by the impact of microRNAs (miRNAs), lncRNAs, or other non-coding
RNAs or RNA binding proteins that affect mRNA stability and structure [93]. Like protein-coding
genes, the expression of non-coding RNAs and other RNA modifying factors are themselves under
epigenetic control by histone modifications and DNA methylation [94].
There has been considerable evidence that miRNAs and other non-coding RNAs play important
roles in epigenetic regulation relevant to cancer [95]. Differential expression of miRNAs has been
reported during mammary gland development and a miRNA signature for progenitor cells has
been identified in mice [96]. miRNAs directly influence stem cell function (miRNA200c) [97] and
cell proliferation by regulating cyclooxygenase-2 (miRNA101a) [98] and PTEN (miRNA-205) [99]
expression, and up-regulating E-cadherin (miRNA-373) [100]. Most miRNAs that regulate tumor
behavior and progression are dysregulated during breast cancer progression. Several miRNAs,
like miRNA-206, miRNA17-5p, miRNA-125a, miRNA-125b, miRNA-200, and miRNA-34 and 31,
which function as tumor suppressor genes, were lost in breast tumors. Expression of miRNA that were
reported to be deregulated and are differentially expressed in normal and breast cancer tissue include
downregulation of miRNA-10b, miRNA-125b, and miRNA-145, and upregulation of miRNA-21 and
miRNA-155 [101]. Furthermore, epigenetically deregulated microRNA-375 has been shown to be
involved in a positive feedback loop with ERα in breast cancer cells [102]. There is an emerging
literature pointing to the complexity of the regulatory consequences of all aspects of the tumorigenesis
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through these mechanisms. However, it is too early to make confident predictions regarding the
implications of alcohol-induced deregulation of these processes and their health consequences.
Unlike genetic mutations, epigenetic alterations are potentially reversible under the right
circumstances, and therefore are targets for medications development for cancer treatment.
Effective treatment for cancer includes the use of DNMT inhibitors and HDAC inhibitors [103].
However, these are blunt tools that do not allow for the selective targeting of the regulation of
individual genes or DNA regions.
Similar to other types of cancer, breast cancer initiates and further progresses at the molecular
level when specific hallmarks of cancer are acquired. Those hallmarks include evading growth
suppressors, sustaining proliferative signaling, avoiding immune destruction, deregulating cellular
energetics, resisting cell death, enabling replicative immortality, acquiring genome instability,
inducing tumor-promoting inflammation, inducing angiogenesis, and activating invasion and
metastasis [104]. A better understanding of these processes and their regulation could potentially enable
a more specific characterization of the epigenetic deregulation, and thereby allow clinicians to target more
specifically processes that are modulated through the deregulation of epigenetic controls or by specific
non-coding RNA networks.
In summary, multiple alcohol effects on specific pathways relevant for carcinogenesis have been
observed, both in human patients and in experimental animal studies. These studies do not exclusively
fit into a model where one mechanism (acetaldehyde or oxidative stress) is responsible for all the
effects of alcohol, or where one type of breast cancer would be particularly susceptible to alcohol use.
However, to the extent acetaldehyde is the culprit (in specific circumstances), it generally requires high
levels of alcohol use and/or a deficiency in the ability to metabolize acetaldehyde. To what extent
acetaldehyde accumulation occurs in breast tissue may not be immediately obvious, since ethanol
metabolism is predominantly hepatic. More indirect consequences of alcohol use, on estrogen levels,
or the effects of estrogen, are another set of pathways by which alcohol could act more broadly,
including in breast tissue. Thus, a broader perspective may be needed. Epigenetic mechanisms
are likely to be affected through other mechanisms than oxidative ethanol metabolism and may be
altered in multiple tissues. However, there is little specific understanding of the impact alcohol has
on these regulatory mechanisms and, in particular there is no information on dose dependency and
temporal consequences of these actions. Despite these insights, however, the overall lack of mechanistic
understanding of these regulatory events is a major impediment in exploring causal factors that are
relevant in human patients.
2. Alcohol Consumption and Breast Cancer: Epidemiological Studies
Chronic heavy alcohol consumption (drinking too much, too often) and binge drinking (drinking too
much, too fast) are risky behaviors that could result in various pathological conditions, including cancer.
Some epidemiological studies have suggested that even moderate alcohol consumption can increase
the risk of breast cancer, although by a small extent [105]. Several recent articles found associations
between modest or high alcohol consumption and a correspondingly moderate or higher increased
risk of breast cancer and concluded that there is a positive dose-response relationship between alcohol
drinking and breast cancer [106]. In addition, several articles reported an association between alcohol
consumption and specific subtypes of breast cancer. However, alcohol was not associated with all
breast cancer subtypes [107], illustrating once again how complex the relationship is between alcohol
use and breast cancer, and how different modes of deregulating the underlying molecular mechanisms
may play a role in breast cancer etiology. In Table 1, we summarize epidemiological studies published
in the last two decades as an example of different studies with variable outcomes.
Examination of Table 1 reveals inconsistencies in the results. While some studies showed increased
breast cancer risk from alcohol, others (e.g., studies 2, 6, 9, and 14) reported no association. It is important
to point out that all observational studies were based on self-report, and there is a wide range of units of
measurement of alcohol intake and the time periods in which these measurements were taken.
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Table 1. Alcohol and Breast Cancer: Recent Epidemiological Studies.
Number Study Design Age (yearrs) at Baseline Data Collection Unit of Measurement Outcomes Ref
2017
1
Longitudinal cohort
NIH-AARP Diet and Health Study
190,325 postmenopausal women
55–70 Self-report
Avg. alcohol consumption (g/day)
in 12 mo. before questionnaire
completion
• Similar associations were found between alcohol consumption
(0.01–10 g/day) and ductal carcinoma in situ (HR = 1.05
[0.93–1.19]) on the one hand and invasive ductal carcinomas
(HR = 1.03 [0.97–1.08]) on the other
[108]
2 Prospective cohortNurses’ Health Study II 93,835 US women 27–44
Semi-quantitative
food questionnaire
Calculated total daily
alcohol consumption
• Alcohol consumption was not associated with breast cancer risk
overall for intake of ≥10 g/day vs. nondrinking (HR = 1.07
[0.94–1.22])
• Positive association between alcohol consumption and breast
cancer was found among women with a family history and folate
intake < 400 µg/day (HR = 1.82 [1.06–3.12])
[109]
3 Sister Study50,884 women 35–74 Self-report Lifetime alcohol intake
• High lifetime alcohol intake (≥230 drinks/year) increased breast
cancer risk (HR = 1.35 [1.15–1.58])
• For binge drinking (HR = 1.29, [1.15–1.45])
[110]
2016
4
Prospective cohort
Nurse’s Health Study
105,972 women
30–55 Semi-quantitative foodfrequency questionnaire Cumulative average alcohol intake
• 10 g/day (HR = 1.1 [1.05–1.15 for luminal A]) and (HR = 1.16
[1.02–1.33 for HER2 BC]), but not with luminal B (HR = 1.08,
[0.99–1.16)]
• Hormonal and non-hormonal mechanisms may play a role in
this association
[111]
5
Case-control
Carolina Breast Cancer Study; 781 Afr.
Am. women; 1014 White women
25–50 Alcohol intake (self-report)most proximal to diagnosis Drinks per week
• Consuming more than 7 drinks/week was significantly associated
with increased risk of ER− (OR = 2.17 [1.25–3.75]) and
triple-negative (ER−/PR−/HER2–) in African American women
but not in White women
[112]
2015
6
Cohort study
French E3N-EPIC
66,481 women
40–65 Self-report diet-historyquestionnaire Cumulative average drinks/day
• No association was found between drinking ≥2 drinks/day (beer,
wine or spirits) and increase in breast cancer risk in
premenopausal period
• ≥2 drinks/day of beer or wine was associated with increased
breast cancer risk (HR = 1.85 [1.19–2.89], 1.33 [1.11–1.58]) in
postmenopausal period
• This relationship was observed primarily in ER+/PR+ breast
cancer risk (HR = 1.32 [1.08–1.60])
[113]
7
Prospective
EPIC Study
334,850 women
35–70 Dietary andlifestyle questionnaires Average lifetime alcohol intake
• 10 g/day increased breast cancer risk by 4.2%
• For intake of 5.1–15 g/day ER+/PR+ (HR = 1.09 [1.00–1.18])
ER+/PR− (HR = 1.13 [0.97–1.31) ER−/PR−/HER2– (HR = 1.18
[0.84–1.66])
• Association between alcohol and breast cancer
[114]
8 Case-control585 cases 28–90
Self-administered
questionnaire
Total number of alcoholic drinks
per week
• <5 drinks per week was associated with increased risk of
ER+ tumors
• In postmenopausal women: ER+ (OR = 2.32 [1.4–3.84]); ER+/PR−
(OR = 2.92 [1.29–6.63]); ER+/PR+ (OR = 1.97 [1.08–3.57])
[115]
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Table 1. Cont.
Number Study Design Age (yearrs) at Baseline Data Collection Unit of Measurement Outcomes Ref
9 Prospective45,233 women 30–49 Self-report
Current number of drinks/week
converted to g/day
• Alcohol intake was not statistically significantly associated with
breast cancer risk, either overall or in different hormone
receptor subtypes
• Overall, breast cancer risk increased with increasing alcohol intake
among women with BMI <25 kg/m2
[116]
10 ProspectiveNHS 30–55 Self-report Cumulative average intake per day
• ER+/PR+/AR+ (HR per drink/day = 1.11 [1.06–1.17])
(AR = androgen receptor)
• ER−/PR−/AR− (HR per drink/day = 0.99 [0.88–1.12])
[117]
11 Prospective cohorts (2)Danish 50+ Self-report Avg. drinks per week
• Marked increase in breast cancer risk for hormone replacement
therapy especially when combined with alcohol
• This effect was primarily restricted to ER+ cases
[118]
2013 and previous
12 Case Control, 2013 Japanese cohort1754 pre- and postmenopausal women 20–79 Self-reported alcohol drinking Avg. consumption g/day
• 23 g/day (OR = 1.39 [95% CI: 1.07–1.80]) in
postmenopausal women
• ER−/PR−/HER2+ (OR = 2.99 [1.08–8.26])
• ER−/PR−/HER2− (OR = 3.72 [1.30–10.67])
• No significant positive association was observed among
premenopausal women
• Among postmenopausal women, no protective effect of folate was
obvious across all subtypes, except ER−/PR−/HER2− (OR = 0.44
[0.20–0.96])
[119]
13 Prospective observational, 2011Nurses’ Health Study 105,986 women Avg. 60
Semiquantitative food
frequency questionnaire Avg. daily consumption in g/day
• At 5–9.9 g/day, or 0.5–1.0 drink: ER+/PR+ (RR = 1.14 [1.02–1.28])
ER−/PR− (RR = 1.25 [1.01–1.54]) ER+/PR− (RR = 1.07 [0.85–1.34])
ER−/PR+ (RR = 1.47 [0.87–2.47])
• Low levels of alcohol were associated with a small increase in
breast cancer risk
[120]
14
Prospective control, 2011
Japanese cohort
19,227 patients
40–64 Food frequency questionnaire Avg. consumption g/day • ≥15 g/day, no significant relation to breast cancer risk• Moderate drinking does not increase breast cancer risk [121]
15 Prospective, 2010 50,757 pre- andpostmenopausal Japanese women 40–69 Self-reported questionnaires Average consumption g/week
• >150 g/week RR = 1.78 (premenopausal), 1.21 (postmenopausal)
• No effect of folate, body weight, flushing due to defective ALDH2 [122]
16 Case control, 2008437 women 25–85
Structured questionnaire
administered by two
interviewers
Average consumption g/day • <1.5 g/day decreases risk of breast cancer (OR = 0.58 [0.34–0.97])• Moderate drinking decreases risk of breast cancer [123]
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There seems to be quite a significant discordance between molecular and epidemiological data.
For example, some molecular studies have ascribed the carcinogenic effect of ethanol, among other
things, to estrogens, which is quite plausible since alcohol increases circulating estrogen levels in
humans [124]. Most epidemiological studies show increased risk between alcohol consumption and
the ER+ type of breast cancer. However, some epidemiological studies show increased risk in the ER−
type (e.g., study 5 in Table 1); ER−/PR− (study 13); ER−/PR+ (study 13); and in TN tumors (studies 5,
7, 10, and 13). In addition, if estrogen is a factor, alcohol should increase the risk of both luminal A and
luminal B tumors since both are ER+; however, increased risk was reported only in luminal A (study #4),
indicating that other factors may mitigate or alter the susceptibility to estrogen. Furthermore, a 2017
study showed that consumption of 15 g of alcohol per day for 8 weeks by postmenopausal women
had no effect on urinary estrogen metabolites [125].
Another area of discrepancy between epidemiology and molecular biology is the role of
acetaldehyde. While acetaldehyde is postulated to play a role in breast cancer, three epidemiological
studies have examined the role of ALDH2*2 (the defective enzyme that causes higher blood
acetaldehyde levels in individuals who consume alcohol) in the development of breast cancer and
reported no association between ALDH2*2 and risk of breast cancer [126]. Furthermore, two studies
examined the association between ALDH2*2 and the risk of breast cancer stratified by alcohol
consumption and concluded that there is no significant effect of the interaction between ALDH2*2 and
alcohol consumption on the risk of breast cancer [127,128]. This prompted Playdon and colleagues
in 2017 [129] to state that the mechanisms linking alcohol and breast cancer risk are incompletely
understood. A recent study by Wang and colleagues [130], however, discussed several mechanisms by
which alcohol may enhance the progression and aggressiveness of existing mammary tumors.
The central theme of observational epidemiology is studying conditions that are identified
as being associated with one or more specific factors, and importantly, to assess likely causal
relationships that could be used to inform health policy recommendations and suggest clinical
interventions. When it comes to non-communicable diseases, major limitations of such studies include
non-replicable and non-causal findings [131]. Indeed, numerous observational studies have reported
substantial causal associations that could not be confirmed in large-scale randomized controlled trials
(RCTs) [132–136]. Such spurious epidemiological findings are usually at least partly due to confounders
that, by themselves, may not be causally related to disease but are associated with other variables
that influence disease risk. Other factors include inevitable measurement errors in assessing both
exposure to the particular condition of interest and to potential confounders [137,138]. These factors
could be particularly relevant in the context of estimates of moderate alcohol consumption as obtained
on the basis of self-reported consumption patterns (see below). A significant question in the field is,
therefore, how investigators can enhance confidence in epidemiological findings and what can be done
to increase validity of causal inferences. One traditional approach to answer such questions has been
to combine the findings from multiple studies in a meta-analysis, as discussed below.
3. Alcohol Consumption and Breast Cancer: Meta-Analyses
Several meta-analyses have examined the association between alcohol consumption and breast
cancer risk (see Table 2). While some studies reported a weak, non-linear, positive association between
alcohol consumption and breast cancer (study G), others (study F) observed a linear increase of breast
cancer risk with an increasing level of alcohol consumption. It is worth noting, however, that study
F defined moderate consumption as consuming ≤50 g per day, which is ~3.6 drinks; moderate
consumption as defined by US dietary guidelines is up to one drink per day for women at 14 g per
drink. Overall, studies agreed that increased breast cancer risk is associated with a high level of alcohol
consumption, and the risk of breast cancer at a low level of alcohol consumption may require further
investigation. Please note comments included in Table 2.
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Table 2. Meta-Analysis Studies on Alcohol Consumption and Breast Cancer.
Study # of StudiesIncluded Definitions of Drinking (g/day) Relative Risk Confidence Interval (95%) Comments Ref.
A
38
10 follow-up
28 case-control
13 g alcohol
(~1 drink)/day 1.10 1.08–1.17
“Modest size of the association and variation in results across
studies leaves the causal role of alcohol in question” [139]
B
29
24 case-control
5 cohort
25 g/d (~1.8 drinks)
50 g/d (~3.6 drinks)
100 g/d (~7.1 drinks)
1.25
1.55
2.41
1.20–1.29
1.44–1.67
2.07–2.80
All doses are higher than moderate drinking [140]
C
85
77 retrospective
8 prospective studies
Drinkers vs. non-drinkers
Dose response 1.11
1.06–1.17
increased risk by 12% for 10 g/day No quantification of amount of alcohol consumed [141]
D
16
4 prospective cohort
12 case-control
Dose response for all ER+, ER−,
PR+ & PR-tumors. Increased risk
10 g ethanol/day
12% ER+
07% ER−
11% ER+/PR+
15% ER+/PR−
ER−/PR−
8%–15%
0%–14%
7%–14%
2%–30%
No significant association
• Two studies conducted in Asia and included in this
analysis showed no association between alcohol and ER+
or ER− tumors
• Information on alcohol intake was collected after diagnosis
[142]
E
110
39 cohort
71 case-control
1.05 1.02–1.08
• Heterogeneity across studies was high
• “Pool estimates should be interpreted with caution”
• Different drinking patterns were not taken into account
[143]
F
118
43 cohort
75 case-control
Light (≤12.5 g or ~1 drink)
Moderate (≤50 g or ~3.6 drinks)
Heavy (>50 g or >3.6 drinks)
1.04
1.23
1.61
1.01–1.07
1.19–1.28
1.33–1.94
According to US dietary guidelines moderate drinking is no
more than one drink/day [144]
G
16
13 case-control
3 cohort
Highest vs. lowest category of
alcohol intake 1.28 1.07–1.52
• Studies captured only ‘current’ drinking
• Weak nonlinear dose-response relationship
• Timing and quantification of alcohol consumption
varied greatly
[145]
H 34cohort studies
≤0.5 drink/day
≤1.0 drink/day
1.04
1.09
1.01–1.07
1.06–1.12
A small number of cohort studies in Asian populations were
included [146]
I
20
prospective cohort
1,089,273 women
≥30 g/day
5 to <15 g/day
1.35 ER+
1.28 ER−
BC even among women
with high folate intake
1.12 ER+
1.19 ER−
1.23–1.48
1.10–1.49
1.07–1.18
1.08–1.31
• Alcohol was positively associated with risk of ER+ and
ER− breast cancer
• Associations were similar beer, wine and spirits
• The associations with alcohol did not vary significantly by
total folate intake
[147]
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Meta-analyses collect and summarize information from many single observational studies
which highlight improbably large effects despite weak evidence. The effect sizes usually shrink
in meta-analyses, and some meta-analyses may control for potential confounding factors [148].
Nonetheless, even these analyses can be biased or misinterpreted [149,150].
There are numerous challenging issues concerning meta-analysis of observational epidemiological
studies. These issues include: different study design (cohort, case-control, prospective, retrospective,
etc.; vast variation in the quality of studies (sample size, drinking assessment, response rate,
missing data, and choice of control in case-control studies, which are more prone to bias than cohort
studies); variation in definition of various confounders, and in confounders included in various studies;
selection bias in meta-analysis by including studies favoring certain outcomes, excluding non-English
articles, or by abstracting incorrect data—the basic premise of meta-analysis being to average out errors,
a slight change in selection criteria can get a different result; and under-reporting of alcohol consumed
in observational studies. In fact, in a recent commentary, Ioannidis [151] echoed the limitations of
meta-analyses in the field of nutritional epidemiology by stating that “meta-analyses become weighted
averages of expert opinions.” In addition, it is well known that positive results are published, negative
results are not. Sensitivity analysis should be used to demonstrate whether removing some of the
selected studies alters the outcome.
A 2017 meta-analysis [152] based on meta-analyses of 20 prospective studies reported a highly
suggestive association between heavy alcohol intake and ER+ breast cancer [≥30 g per day of alcohol
consumption versus nondrinkers, RR = 1.35 (1.23–1.48)]. The association between alcohol and ER-breast
cancers was classified as weak, based on 17 meta-analyses. The study also reported a strong effect
of “moderate” alcohol intake [12.5 g to 50 g per day—the equivalent of 1 to 3.7 drinks per day,
versus non-drinkers, RR = 1.28 (1.10–1.49)]. It should be pointed out again that what is classified as
moderate drinking is not moderate according to US dietary guidelines for alcohol consumption [153].
4. Association or Causation
Persistent methodological problems continue to plague the field of observational epidemiology,
which may account for some of the inconsistency and uncertainty reflected in these studies.
These include measurement error and confounding factors. Measurement error is especially
problematic in alcohol research, which depends on self-report of alcohol consumption, an imperfect
measure that more often than not leads to underestimates, particularly for moderate drinkers [154].
Additionally, measurement error has generated intense debate in, for example, the epidemiology of
diet-induced cancer, leading to either missing important nutrition-cancer correlations, or reported
false, deleterious, or protective associations [155]. Multiple confounders can collectively distort an
exposure-outcome association and often yield misleading results [156]. These factors may invalidate
causal interpretations of observed associations.
Numerous observational studies have associated alcohol consumption with breast cancer.
While heavy alcohol consumption may increase the risk of breast cancer, linking alcohol
consumption—especially in moderate amounts—to cancer, based solely on observational studies, is rarely
definitive. It is intrinsically difficult to adequately account for confounding factors, including other lifestyle
factors that are causally linked to carcinogenesis, and significant inaccuracies in estimates of long-term
alcohol drinking history. The concept of causality is central to the development of interventions
designed to reduce exposure to cancer-causing risk factors. Numerous causal risk factors have been
linked to cancers (e.g., human papilloma virus and cervical cancer; ionizing radiation and leukemia;
radon and lung cancer; aflatoxin and liver cancer; asbestos and mesothelioma—to name a few) only
after the accumulation of sufficient evidence derived from epidemiological studies, clinical research,
and mechanistic studies in laboratory animals [157]. The framework of causation in epidemiological
studies was developed in 1965 by British medical statistician Sir Austin Bradford Hill [158],
and includes the following minimal conditions needed to establish a causal relationship: temporality,
strength of association, dose-response relationship, specificity, consistency (replicated results),
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plausibility (agrees with currently accepted understanding of pathological processes), experiment,
coherence, and consideration of alternate explanations. Generally, epidemiological studies do not meet
all of these criteria. The increasing availability of large scale molecular information science is entering
a new era in which potential causal inferences are increasingly based on knowledge derived from
mechanistic studies rather than exclusively relying on observational epidemiological studies, which
by itself is generally “insufficient to establish causality” [157]. In fact, increasing concern about the
validity of claims from biomedical research and particularly from observational research have been
voiced [159,160]. Moreover, “media publicity about the findings is often based on novelty, rather than
on reproducibility or scientific credibility.” [157]. Clearly, there is a need for independent supportive
information to substantiate the observational associations. Different approaches are being developed
that attempt to provide such independent validation.
4.1. Strengthening Causal Inference by Genetic Epidemiology through Mendelian Randomization
When confounding factors are present in a conventional epidemiological study but cannot be
controlled for, Mendelian randomization is a widely used approach to address some of the problems of
weak observational studies. Mendelian randomization combines genomic and epidemiologic methods
to obtain more unbiased estimates of causal associations and offers a potential way to correct, in part,
for the difficulties introduced by confounding factors and measurement errors.
A Mendelian randomization study published in 2007 by Smith and colleagues [161] using data
from the British Women’s Heart and Health Study reported that many nongenetic modifiable risk
factors occur in clusters. Thus, adjusting for confounders in observational studies will be hard because
it will not always be clear which factors are confounders. The study concluded “These data illustrate
why observational studies have produced misleading claims regarding potentially causal factors.”
However, different approaches are being discussed on how to address these and other problems [162].
In alcohol research, no Mendelian randomization studies, to our knowledge, were performed
that aimed to assess the relationship between alcohol use and breast cancer. However, alcohol-related
studies using Mendelian randomization in other contexts have been based on the fact that
genes involved in alcohol metabolism are polymorphic, and different allelic variants result in
alcohol-metabolizing enzymes with various activities that can serve as proxies for different degrees of
alcohol consumption. In other words, for polymorphic genes, allelic variants can produce physiological
and/or biochemical states that encourage different levels of drinking and therefore reflect various
levels of alcohol exposure at the population level.
4.2. Marginal Structural Modeling and Agent-Based Modeling
Etiologies of complex diseases such as cancer are characterized by inference and multiple
interacting causal effects [163]. Many statistical methods used in epidemiology include “main effects
only,” regression-based models which assume that the actions of multiple causes are unidirectional
and independent. To illuminate causality in epidemiological research, marginal structural models
were introduced by VanderWeele et al. [164] in 2010. The advantage of using marginal structural
models, as an alternative to regression models to test for sufficient cause interactions is that modeling
assumptions are made on the relationship between the causes of interest and the confounding variables,
and thus are more plausible. An alternative and complementary approach to elucidate complex causal
interdependencies involves agent-based modeling, introduced in 2015 by Marshall and Galea [163].
Agent-based modeling is an apt way of tackling independence of causal effects and non-interference
by simulating counterfactual outcomes. The goal is to make causal inferences as independent of
theoretical opinions and expert judgement as possible [165]. To what extent these approaches could
help support causal inferences from observational studies in particular on the impact of light or
moderate alcohol consumption on breast cancer remains to be established.
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4.3. Molecular Pathological Epidemiology
With the National Institutes of Health currently encouraging “precision medicine” to speed the
movement of basic discoveries from the lab to the clinic [166], there are good reasons to consider
applying approaches involving translational and interdisciplinary studies to the field of alcohol
research. The concept of precision medicine implies that pathogenesis results from the unique
interactions between cells involving genetic and epigenetic alterations, and lifestyle factors that
vary between individuals.
The premise of classical epidemiology is that patients with the same diagnosis (e.g., breast cancer)
have similar causes and disease progression despite variations in molecular pathology. Because each
tumor possesses its own unique characteristics, such as molecular makeup, microenvironment,
and communications within and between cancer and host cells, “it is essential that epidemiologic
research rely on modern molecular classification of disease.” [167]. Therefore, inferences of causation
can be strengthened by the interpretation of data from genomics, epigenomics, metabolomics,
transcriptomics, exposomics, proteomics, molecular epidemiology, microbiome, and immunomics,
among others [168]. Thus, causal claims should be based on different balances of contributions from
empirical information (association studies) and mechanistic information [168].
Modern epidemiology is starting to incorporate genomic medicine and biomedical sciences,
which is contributing a lot to the evolving field of molecular pathological epidemiology (MPE).
The concept of MPE was developed in 2010 by Ogino and Stampfer [169]. These investigators
noted that colorectal cancer, like breast cancer, is not a single disease, and yet was classified by
epidemiological studies into a limited number of groups under the assumption that tumors with
similar characteristics have arisen through common mechanisms. MPE integrates information about
exposure, patient characteristics including immunity, and the consequent dysfunction of physiological
events that lead to pathology (see Figure 3) [170].
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For example, studies on colorectal cancer—a suitable disease model for the immunology-MPE
approach, given rich microbiota and immune tissues of intestines, and the well-established carcinogenic
role of intestinal inflammation—provided insights into immunomodulating effects of aspirin,
vitamin D, inflammatory diets, and omega-3 polyunsaturated fatty acids [171]. Previously, the same
authors found that higher pre-diagnosis levels of soluble tumor necrosis factor receptor type II
(sTNF-RII) were associated with about a 48% increase in overall mortality in patients with colorectal
cancer; however, among regular aspirin users, increasing levels of sTNF-RII were not associated with
worse mortality [172]. Similarly, using MPE, Babic and colleagues [173] showed that higher levels of
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plasma leptin were associated with increased risk of pancreatic cancer in men, whereas in women
a single nucleotide variant at the leptin receptor gene (rs10493380) was associated with pancreatic
cancer risk. In addition, Yuan and colleagues [174] identified novel prognostic markers in patients
with pancreatic cancer which implicated altered tricarboxylic acid metabolism in pancreatic cancer
progression. They showed that two metabolites in the tricarboxylic acid cycle, isocitrate and aconitate,
together with polymorphisms in Aconitase 1 were significantly associated with survival of patients
with pancreatic cancer.
The transdisciplinary field of MPE “can advance biomedical and health research by linking
exposure to molecular pathologic signatures, enhancing causal inference, and identifying potential
biomarkers for clinical impact.” [167]. The field has so far mostly been focused on cancer, including,
lung, pancreatic, and colorectal cancer. Characterization of molecular pathology in cancer is critical to
link risk factors to plausible pathogenic mechanisms and cancer etiology [175], and consequently to
predicting response or resistance to treatment.
MPE enables researchers to provide evidence about how endogenous and exogenous factors
may interact and contribute to tumor evolution, and about the diversity of tumor phenotypes [176].
The concept that tumor subtypes that are genuinely biologically distinct are likely also to possess
distinct etiologies has been well supported by the systematic analysis of etiologies and subtypes of
bilateral breast cancers [177].
Molecular classification plays a pivotal role in MPE, with the underlying premise that breast
cancers that share similar features are likely also to possess similar etiologies and behave in a similar
manner in their progression and their response to treatment. Classically, etiologic heterogeneity of
tumor subtypes is accomplished in case-control studies by comparing the odds ratios of candidate risk
factors between the tumor subcategories and a common control group. This approach is incomplete,
since many genetic risk factors for cancer have not been identified. Unfortunately, hitherto the MPE
approach has not been used to evaluate the impact of alcohol use as a risk factor for breast cancer.
5. Conclusions
The discussion presented in this review has aimed to highlight both the broad scope of possible
molecular mechanisms that may contribute to the onset or progression of cancers of the breast, as well
as our ignorance of the detailed underlying processes and their regulation that dictates the outcome.
Some of these potential processes influenced by alcohol use are likely to require relatively high levels
of drinking and prolonged exposure. However, other mechanisms, such as those mediated by various
epigenetic controls, are as yet poorly characterized and, as a result, remain unpredictable. The survey
of the multiple epidemiological studies and meta-analyses also highlight the substantial variability that
exists in the relative risk estimates, which are particularly difficult to interpret when light to moderate
drinking frequencies are considered.
What is the reason to be so concerned about differentiating between potential cancer risk at high
and moderate or low levels of drinking? Why is it important to have an understanding of the causative
mechanisms of breast cancer and, more particularly, whether alcohol intake had anything to do with
increasing the risk of specific subtypes of breast cancer?
Alcohol has a social function that is important in many people’s lives. For the vast majority of
drinkers this social function is associated with occasional or moderate drinking. The relative risk of
negative consequences, including the relative risk of developing breast cancer, is therefore an issue
that has to be weighed against these positives. Most observational epidemiological studies are in
agreement that heavy drinking carries significant and diverse negative consequences and should be
actively avoided. However, the negative consequences of light or moderate drinking are minimal,
even in the majority of studies that show a detectable odds ratio for cancer or other diseases at these
lower levels.
The important question in this context is then whether a particular individual carries a higher
risk than the general population as a consequence of specific susceptibilities that may vary from
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one person to another. It may be important, therefore, to be able to advise individual patients
on specific vulnerabilities, either in their susceptibility to potential damaging effects of alcohol
(e.g., those expressing the defective ALDH2*2 isoform) or with significant risk factors for developing
breast cancer, BRCA1 or BRCA2 mutations the impact of which may increase their susceptibility to
other potential risk factors. In addition, women with a positive family history of breast cancer, or are
using contraceptive pills or hormone replacement therapy may be at higher risk.
A better understanding of the mechanistic basis of these susceptibilities then becomes a critical
element. For this it is essential to obtain a more detailed knowledge of the molecular mechanisms
by which alcohol use can impact cell function over prolonged periods. Such insights would enable
the development of biomarkers that are mechanism-based and that, if well understood, could give
guidance both to a physician who is asked to advise a patient, and to the individual patient who has
to weigh these decisions. It would also facilitate the development of early detection tools that would
help distinguish relatively innocuous indicators from more significant malignancies, and, of course,
assist in the development of more individually targeted treatment modalities, the ultimate goal of
“personalized medicine”. This is the promise of an approach such as that proposed under the umbrella
of MPE.
Breast cancer is a dreadful disease that can be treated effectively if caught early. In view of
variable characteristics of different subtypes of breast cancer, the various susceptibilities of women
to different risk factors and extents of exposure, as well as their various genetic susceptibilities,
determining the molecular pathologic signatures is essential to facilitate better causal inference,
and identify potential biomarkers for clinical impact and response to treatment. This endeavor
will benefit greatly from the application of a multidisciplinary effort such as MPE, which encompasses
various medical fields, including immunology, in addition to observational epidemiological studies.
MPE facilitates the realization of precision medicine [171]. In the words of Nishi and colleagues [167]:
“Molecular pathological characterization of diseases such as cancer is crucial to link risk factors to
plausible pathogenic mechanisms, to estimate the natural history of an individual tumor, and to
better predict the response/resistance to treatment or lifestyle intervention to maximize its benefit to
each individual.”
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